Investing guide
Raising a HealthTech round
What health technology investors actually check, and the diligence that kills otherwise strong companies.
7 min read · Updated 2026
Health technology fundraising follows the general venture pattern with three additions: regulatory risk, reimbursement risk and a sales cycle long enough to swallow a runway. Investors who focus on the sector are underwriting those three, whatever else the pitch says.
The four questions behind every meeting
Who pays, and is that budget already allocated to something else. Can the product get through security, integration and clinical governance in a reasonable time. Is there evidence that the clinical or financial effect is real. Can this team recruit both clinical and technical credibility.
Metrics that carry weight by stage
At seed, investors buy the founding team and the specificity of the wedge. At Series A, they want repeatability: several customers acquired the same way, with a shortening sales cycle. At Series B and beyond, they want net revenue retention, gross margin after implementation cost, and proof that deployment does not require the founders.
- Report contracted revenue and live revenue separately. Investors will find the gap anyway.
- Show implementation time trending down. It is the clearest scalability signal in the sector.
- Be explicit about pilot revenue versus renewed contracts.
Regulatory and evidence posture
Have a clear, defensible position on whether your product is a regulated medical device in each market you sell in, and who signed off on that view. Investors do not expect every company to be cleared. They expect the founders to know exactly which side of the line they are on and why, and to have budgeted for the path if they are on the regulated side.
Common failure modes in diligence
Customer references who describe a pilot as a purchase. Margins that quietly assume free implementation labour. A clinical advisory board with famous names and no involvement. Data rights that do not survive a customer contract review. Each of these is recoverable if you raise it first, and expensive if the investor finds it.
Key signals
- Investors underwrite regulatory, reimbursement and sales cycle risk above all.
- Falling implementation time is the strongest scalability signal in health technology.
- Separate contracted from live revenue before diligence does it for you.
- Know precisely whether you are a regulated device, and be able to defend it.